Osteoporotic fractures: mortality and quality of life

Unit of Rheumatology, Department of Internal Medicine, G. Martino Hospital, Messina, Italy.
Panminerva medica (Impact Factor: 2.28). 04/2007; 49(1):21-7.
Source: PubMed

ABSTRACT Osteoporosis is a widespread disease, affecting about 75 million people, mostly postmenopausal women. It is called ''the silent disease'', since there are very few associated symptoms: anyway osteoporotic fractures are the chief clinical feature, with an enormous burden on health related quality of life and mortality. The aim of this study was to review the literature on the evaluation of mortality and health related quality of life as consequences of osteoporotic fractures. Fractures, the clinical manifestation of osteoporosis, are extremely common and are devastating both to affected patients and to society that must bear the enormous cost of fracture treatment and subsequent disability. Hip and spine fractures are linked with increased mortality, and all fractures may lead to disability and reduced quality of life. Since patients with osteoporosis usually have no symptoms before fracture, early diagnosis and treatment of the disease are of great importance to the quality of life in these patients. To reduce mortality, attention must focus on optimising health status preoperatively, preventing postoperative complications, and, when these complications develop, providing optimal specialist medical care.

Download full-text


Available from: Gianluca Bagnato, Feb 15, 2015
1 Follower
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Postmenopausal osteoporosis is an increasing worldwide health concern affecting an estimated 200 million individuals. Despite a wide range of available treatment options, many patients are not being treated or discontinue therapy. The ongoing need for new osteoporosis therapies has led to the development of new selective estrogen receptor modulators (SERMs) with an ideal tissue selectivity profile and beneficial effects on bone without undesirable effects on the endometrium and breast. Bazedoxifene acetate, a novel SERM in clinical development for the prevention and treatment of postmenopausal osteoporosis, resembles this ideal profile more closely than other currently available SERMs. Results from large prospective phase III trials showed that it increases bone mineral density, reduces bone turnover rate and decreases the risk for new vertebral fractures. Moreover, based on a post hoc analysis of a subgroup of women with a higher risk for fracture, bazedoxifene was demonstrated to significantly reduce the incidence of nonvertebral fractures compared with both raloxifene hydrochloride and placebo. Furthermore, it was reported to be well tolerated, with a favorable safety profile and no evidence of endometrial or breast tissue stimulation. Bazedoxifene represents an important new treatment option for women at risk for osteoporosis and fracture.
    Drugs of today (Barcelona, Spain: 1998) 07/2009; 45(7):507-20. DOI:10.1358/dot.2009.45.7.1395293
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The negative impact of vertebral and hip low-energy fractures on health-related quality-of-life (HRQOL) has been demonstrated previously, but few prospective long-term follow-up studies have been conducted. This study aims to (i) investigate the changes and long-term impact of vertebral or hip fracture and between fracture groups on HRQOL in postmenopausal women prospectively between two and seven years after the inclusion fracture, (ii) compare HRQOL results between fracture and reference groups and (iii) study the relationship between HRQOL and physical performance, spinal deformity index and bone mineral density at seven-year follow-up. Ninety-one women examined two years after a low-energy vertebral or hip fracture were invited to a new examination seven years after the diagnosis. HRQOL was examined using the SF-36 questionnaire and was compared with an age and sex-matched reference group. Physical function was assessed using tests and questionnaires. Bone mineral density was measured. Radiographs of the spine were evaluated using the visual semiquantitative technique. A longitudinal and cross-sectional design was used in this study. Statistical analyses included descriptive statistics, Student's t-tests, ANCOVA, and partial correlation. Sixty-seven women participated. In the 42 women (mean age 75.8, SD 4.7) with vertebral fracture as inclusion fracture, bodily pain had deteriorated between two and seven years and might be explained by new fracture. Remaining pronounced reduction of HRQOL was seen in all domains except general health and mental health at seven-year follow-up in women with vertebral fractures compared to the reference group (p < 0.05). All 25 women (mean age 75.0, SD 4.7) with hip fracture as inclusion fracture had no significant changes in HRQOL between two and seven years and did not differ from the reference group regarding HRQOL after seven years. The vertebral group had significantly lower values for bodily pain, vitality, role-emotional function and mental health compared to the hip group. HRQOL showed a positive relationship between physical activity, static balance and handgrip strength. The long-term reduction of HRQOL in women with vertebral fracture emerged clearly in this study. The relationships between HRQOL and physical performance in women with vertebral and hip fracture raise questions for more research.
    BMC Musculoskeletal Disorders 11/2009; 10(1):135. DOI:10.1186/1471-2474-10-135
Show more